Jason Loveridge

Jason Loveridge was the founder of Parvulus Suisse SA, founded in 2011, where he held the title of Chief Executive Officer from 2011 to 2014, and Invex Therapeutics Ltd., founded in 2019, where he held the title of Non-Executive Chairman from 2019 to 2023.
Currently, he is the Chief Executive Officer at 4SC AG since 2016, and a Director at Corticrine Ltd., Warambi Ltd., and Invex Therapeutics Ltd.
(United Kingdom).
He was also a Director & Investment Manager at Korda & Co. from 1991 to 1995, and a Principal at BioPharma Capital Ltd.
in 2003.
Additionally, he was a Non-Executive Director at Biofrontera AG, Actinogen Medical Ltd., and Parvulus Medical SAS, and a Gérant Sénior at IT Asset Management SA from 2005 to 2007.
He was also an Independent Non-Executive Director at Resonance Health Ltd.
from 2013 to 2017, and a Non-Executive Director at Actinogen Medical Ltd.
from 2017 to 2018.
Furthermore, he was a Director at Anaconda Pharma SASU, Executive Director & Owner at Warambi SARL from 2005 to 2020, and a Director at JDS BioPharma Pty Ltd.
from 2006 to 2020.
Dr. Loveridge received a doctorate degree from the University of Adelaide in 1988 and an undergraduate degree from The University of New South Wales in 1982.